Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues

Drug Metabolism and Disposition

Volumn 35, Issue 4, 2007, Pages 682-688

  DeLozier, Tracy C ^a   Kissling, Grace E ^a   Coulter, Sherry J ^a   Dai, Diana ^a   Foley, Julie F ^a   Bradbury, J Alyce ^a   Murphy, Elizabeth ^a   Steenbergen, Charles ^b   Zeldin, Darryl C ^a   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HEART MUSCLE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AORTA; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CARDIOVASCULAR SYSTEM; CORONARY VESSELS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXYGENASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34047173527     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012823     Document Type: Article

References (41)

1. Busse R and Fleming I (2003) Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci 24:24-29.
2. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.
3. Campbell WB and Harder DR (1999) Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84:484-488.
4. Capdevila JH, Falck JR, and Harris RC (2000) Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41:163-181.
5. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, et al. (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561.
6. DeLozier TC, Dai D, Coulter SJ, Bradbury JA, Elizabeth MY, Zeldin DC, and Goldstein JA (2006) Detection of human CYP2Cs in heart, aorta and coronary tissues. Presented at the annual meeting of the Federation of American Societies for Experimental Biology, San Francisco, CA, April 1-5, 2006. FASEB J 20:A1111-c-1112A.
7. Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, and Medhora M (2006) Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol 291:H517-H531.
8. Elbekai RH and El-Kadi AO (2006) Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112:564-587.
9. Enayetallah AE, French RA, Thibodeau MS, and Grant DF (2004) Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447-454.
10. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (Lond) 401:493-497.
11. Fleming I (2001) Cytochrome p450 and vascular homeostasis. Circ Res 89:753-762.
12. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R (2001) Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88:44-51.
13. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, et al. (1992) Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281 (Pt 2):359-368.
14. Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA, Zeldin DC, and Leeder JS (2006) Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther 319:523-532.
15. Gottlieb RA (2003) Cytochrome P450: major player in reperfusion injury. Arch Biochem Biophys 420:262-267.
16. Granville DJ, Tashakkor B, Takeuchi C, Gustafsson AB, Huang C, Sayen MR, Wentworth P Jr, Yeager M, and Gottlieb RA (2004) Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci USA 101:1321-1326.
17. Gross ER, Nithipatikom K, Hsu AK, Peart JN, Falck JR, Campbell WB, and Gross GJ (2004) Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol 37:1245-1249.
18. Hunter AL, Bai N, Laher I, and Granville DJ (2005) Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction. Vasc Pharmacol 43:213-219.
19. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
20. Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, and Gutterman DD (2006) Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol 290:H491-H499.
21. Li PL and Campbell WB (1997) Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80:877-884.
22. Lin JHC, Kobari Y, Zhu Y, Stemerman MB, and Pritchard KAJ (1996) Human umbilical vein endothelial cells express P450 2C8 mRNA: cloning of endothelial P450 epoxygenase. Endothelium 4:219-229.
23. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
24. Lu T, Ye D, Wang X, Seubert JM, Graves JP, Bradbury JA, Zeldin DC, and Lee HC (2006) Activation of KATP channels by endogenous cytochrome P450 epoxygenase metabolites of arachidonic acid: cardiac and vascular KATP channels are activated by epoxyeicosatrienoic acids through different mechanisms. J Physiol 575 (Pt 2):627-644.
25. McGuire JJ, Ding H, and Triggle CR (2001) Endothelium-derived relaxing factors: a focus on endothelium-derived hyperpolarizing factor(s). Can J Physiol Pharmacol 79:443-470.
26. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, and Busse R (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118:5489-5498.
27. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science (Wash DC) 285:1276-1279.
28. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
29. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily [published erratum appears in Biochemistry (1993) 32:1390]. Biochemistry 30:3247-3255.
30. Russo G, Leopold JA, and Loscalzo J (2002) Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vasc Pharmacol 38:259-269.
31. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, et al. (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95:506-514.
32. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510.
33. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, et al. (2004) Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110:2132-2136.
34. Spiecker M and Liao JK (2005) Vascular protective effects of cytochrome p450 epoxygenasederived eicosanoids. Arch Biochem Biophys 433:413-420.
35. Thum T and Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355:979-983.
36. Voetsch B, Jin RC, and Loscalzo J (2004) Nitric oxide insufficiency and atherothrombosis. Histochem Cell Biol 122:353-367.
37. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
38. Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, Degraff LM, Falck JR, Krausz K, Gelboin HV, Morgan JP, et al. (2004) Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol 66:1607-1616.
39. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK, and Zeldin DC (2001) Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 60:310-320.
40. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, and Rane A (2003) Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13:715-720.
41. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, and VanRollins M (2001) EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol 280:H2430-H2440.